AT-7519 - CAS 844442-38-2
Catalog number: 844442-38-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H17Cl2N5O2
Molecular Weight:
382.24
COA:
Inquire
Targets:
CDK
Description:
AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
Purity:
0.98
Appearance:
white solid powder
Synonyms:
AT-7519, AT7519, AT 7519, AT-7519 free base
MSDS:
Inquire
InChIKey:
OVPNQJVDAFNBDN-UHFFFAOYSA-N
InChI:
InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)
Canonical SMILES:
C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl
Current Developer:
Astex Therapeutics
1.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D1, Staud F, Ceckova M. Cancer Chemother Pharmacol. 2015 Jul;76(1):105-16. doi: 10.1007/s00280-015-2772-1. Epub 2015 May 19.
PURPOSE: ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro: P-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated protein 1 (ABCC1).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


THZ2
(CAS: 1604810-84-5)

THZ2, an analog of THZ1, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor which overcomes the insta...

LOR-253
(CAS: 916151-99-0)

LOR-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) mast...

QS-1189

QS-1189 is a reversible, high selective, orally available cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. QS-1189 exhibits antitumor ac...

CAS 1604810-83-4 THZ1

THZ1
(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

CAS 718630-59-2 PHA-793887

PHA-793887
(CAS: 718630-59-2)

PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. Although toxicity was acceptable at initial dos...

CAS 186692-46-6 Seliciclib

Seliciclib
(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

CAS 1397219-81-6 BS-181 HCl

BS-181 HCl
(CAS: 1397219-81-6)

BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

CAS 161058-83-9 NU2058

NU2058
(CAS: 161058-83-9)

NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.

Chemical Structure

CAS 844442-38-2 AT-7519

Quick Inquiry

Verification code

Featured Items